Landscape Capital Management L.L.C. Purchases New Shares in Teleflex Incorporated (NYSE:TFX)

Landscape Capital Management L.L.C. purchased a new stake in Teleflex Incorporated (NYSE:TFX) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,554 shares of the medical technology company’s stock, valued at approximately $515,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Janus Henderson Group PLC raised its position in Teleflex by 18.5% in the 1st quarter. Janus Henderson Group PLC now owns 962,391 shares of the medical technology company’s stock valued at $290,796,000 after buying an additional 150,201 shares during the last quarter. Marshall Wace LLP raised its position in Teleflex by 2.1% in the 1st quarter. Marshall Wace LLP now owns 596,777 shares of the medical technology company’s stock valued at $180,322,000 after buying an additional 12,502 shares during the last quarter. Parnassus Investments CA raised its position in Teleflex by 2.2% in the 1st quarter. Parnassus Investments CA now owns 504,567 shares of the medical technology company’s stock valued at $152,460,000 after buying an additional 11,033 shares during the last quarter. Marshall Wace North America L.P. raised its position in Teleflex by 32.2% in the 1st quarter. Marshall Wace North America L.P. now owns 494,782 shares of the medical technology company’s stock valued at $149,502,000 after buying an additional 120,411 shares during the last quarter. Finally, Northern Trust Corp raised its position in Teleflex by 10.1% in the 1st quarter. Northern Trust Corp now owns 481,082 shares of the medical technology company’s stock valued at $145,364,000 after buying an additional 44,093 shares during the last quarter. 91.28% of the stock is owned by institutional investors and hedge funds.

Shares of Teleflex stock traded up $1.35 during trading hours on Friday, hitting $369.81. 151,300 shares of the company’s stock traded hands, compared to its average volume of 263,176. Teleflex Incorporated has a 12-month low of $226.02 and a 12-month high of $373.84. The stock has a market capitalization of $17.03 billion, a price-to-earnings ratio of 37.35, a PEG ratio of 2.44 and a beta of 1.02. The company has a fifty day simple moving average of $345.78 and a 200-day simple moving average of $308.65. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.52 and a quick ratio of 1.59.

Teleflex (NYSE:TFX) last announced its earnings results on Thursday, August 1st. The medical technology company reported $2.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.07. Teleflex had a return on equity of 18.57% and a net margin of 10.78%. The firm had revenue of $652.50 million during the quarter, compared to analyst estimates of $637.06 million. During the same period last year, the firm posted $2.47 EPS. The business’s revenue was up 7.0% compared to the same quarter last year. On average, analysts forecast that Teleflex Incorporated will post 11.03 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, September 16th. Stockholders of record on Thursday, August 15th will be given a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 0.37%. The ex-dividend date is Wednesday, August 14th. Teleflex’s dividend payout ratio is presently 13.74%.

A number of equities research analysts recently commented on TFX shares. Morgan Stanley increased their price target on Teleflex from $345.00 to $392.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. Wells Fargo & Co started coverage on Teleflex in a research report on Tuesday, June 11th. They issued an “outperform” rating and a $345.00 price target for the company. Barclays increased their price target on Teleflex from $309.00 to $356.00 and gave the company an “equal weight” rating in a research report on Monday, August 5th. Needham & Company LLC reaffirmed a “buy” rating and set a $403.00 target price (up from $325.00) on shares of Teleflex in a research report on Friday, August 2nd. Finally, Raymond James raised their target price on Teleflex from $350.00 to $420.00 and gave the company a “strong-buy” rating in a research report on Friday, August 2nd. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $367.67.

In other news, Director Benson Smith sold 8,500 shares of the stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $294.56, for a total transaction of $2,503,760.00. Following the completion of the transaction, the director now owns 85,300 shares in the company, valued at approximately $25,125,968. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Cameron P. Hicks sold 700 shares of the stock in a transaction on Tuesday, June 18th. The stock was sold at an average price of $330.70, for a total value of $231,490.00. Following the transaction, the vice president now owns 7,076 shares of the company’s stock, valued at approximately $2,340,033.20. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 46,953 shares of company stock valued at $15,020,002. Insiders own 2.36% of the company’s stock.

Teleflex Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It offers vascular access products that comprise Arrow branded catheters and related devices, including catheter positioning systems for use in the administration of intravenous medications and other therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site; and devices for treating coronary and peripheral vascular disease.

Featured Story: What is a Reverse Stock Split?

Want to see what other hedge funds are holding TFX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teleflex Incorporated (NYSE:TFX).

Institutional Ownership by Quarter for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.